T-Cypher Bio is an early-stage, innovative biotechnology company based in Oxford, UK. We believe that TCR-based therapeutics have the potential to transform the treatment of solid tumours, as well as autoimmune, inflammatory, and infectious diseases. Yet challenges in the identification of therapeutically relevant targets and TCRs has limited the application of such therapies. T-Cypher's integrated platform, D-Cypher, overcomes these challenges.